Trouble reading this e-mail? View it in your browser.

7 July 2016
Header image
From our blog

From our blog

The Complexity of Cancer Means Multiple Solutions Must Be Sought (Guest blog)
06 July 2016 by Nils Wilking

That healthcare budgets are facing significant challenges in covering the cost of innovative cancer drugs is not news – clearly new financing mechanisms are required urgently. Nevertheless, beyond prices, patients are facing long, drawn-out negotiating processes as well as a lack of understanding on the part of some healthcare providers when it comes to new treatment options and data, both of which delay access.

Read more

Events calendar

Events Calendar

Addressing the changing landscape for EU clinical trials
From 07/09/2016 to 09/09/2016 (Brussels)

With the advent of new European regulations, as well as the introduction of innovative research methods and technologies, the clinical trial landscape is fast evolving. 

EORTC will be hosting two events in September, addressing the topics of new EU regulations and new research methodologies in clinical trials:

Navigating Safely through the Regulatory Triangle: (Clinical Trials – In vitro Diagnostics – Data Protection) is a one-day course, which examines how the various elements of these regulations come together, and their potential impact on clinical research. It is targeted at: regulatory specialists in (bio)pharma; representatives of patient advocacy groups; and any other person with an interest in clinical trial regulations and drug development competitiveness in Europe.

Where: Brussels, Belgium – When: 7 September 2016

Innovation and Biomarkers in Cancer Drug Development (IBCD), a first-of-a-kind joint meeting by EORTC, NCI, EMA, and AACR explores the complexity of new cancer drug and biomarker development requirements. IBCD 2016 will help forge multi-stakeholder approaches to cancer drug development with new cancer biomarkers, with an extensive scientific programme that includes input from regulators, industry, academia, patients and payers.

Where: Brussels, Belgium – When: 8-9 September 2016

Read more

Events Calendar

Life Sciences Baltics 2016
From 14/09/2016 to 15/09/2016 (Vilnius, Lithuania)

Life Sciences Baltics 2016 is the only international forum in the Baltics for world-class biotechnology, pharmaceutical and medical devices experts from all around the world. It provides a unique opportunity to explore the new horizons of partnerships, exchange ideas and seek progress through networking. Discover enormous potential and passion in the field of life sciences in Lithuania and the Baltics – the gateway to emerging markets.

For more information about the event, click here.

Read more

What we are reading

What we are reading

State premium can secure antibiotics
06 July 2016 (Dagens Nyheter)

In order to secure access to important antibiotics, the government has decided to investigate whether a model with state premiums may be worth testing. The proposal will be presented today, Tuesday, at the “Almedalen political week” in Visby.

While the use of antibiotics must be reduced in order to slow the development of AMR, health care must also have access to effective antibiotics and new antibiotic agents must be developed. But to invest in R&D for new medicines that preferably should not be used is not interesting for pharmaceutical companies.

- Antibiotics that are used only in rare cases will be very expensive and not profitable to use in Sweden with our situation as regards AMR. We need to find a new economic model to ensure the availability, says minister for health, Mr. Gabriel Wikström.

The government has now given the Public Health Agency the task to examine whether a system including state premiums to pharmaceutical companies would be worth trying. The premium would guarantee an income to the companies and thus helping to secure that pharmaceutical companies will develop new antibiotic agents.

- If we find a good model, it can also entice companies to invest in new antibiotics. For antibiotics the usual economic models for medicine, where large initial costs of research are paid through high prices at the beginning of the product cycle, do not apply. That model does not work for antibiotics that are only kept as a reserve and should preferably not be used at all, says Gabriel Wikström.

The model of a premium system is based on a proposal by the trade association LIF.

- What's really exciting is that we can be the first to solve this problem. If it works, we believe that it will inspire other countries, says Karolina Antonov, head of analysis at LIF.

The article was originally published here (in Swedish).

Read more

What we are reading

State premiums can secure new antibiotics
06 July 2016 (LIF – the research-based pharmaceutical industry in Sweden)

The Swedish government has decided to investigate whether a model with state premiums for new antibiotic medicines may be worth testing in actual practice. The proposed model is designed to create incentives both to market new antibiotics in Sweden, and to overcome the problem that too few new antibiotics are being developed because it is not economically viable. New antibiotics should only be used for a very small number of patients, in order to fight the growing problem with AMR.

Read more

What we are reading

Annual Activity Report
06 July 2016 (IMI)

2015 was a productive year of transition for the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU). Building on the success of IMI1 JU, the IMI2 JU programme aims to provide European citizens with more effective and affordable medicines and treatments. Our unique model has created a neutral platform where pharmaceutical companies, academia, patients, SMEs, regulators, and all other stakeholders involved in the complex process of innovative medicines development, come together in a public-private partnership (PPP) to address major challenges of public health interest. Sharing knowledge at an unprecedented level amongst all players will ensure the most efficient path forward and will create both a vibrant innovation ecosystem in Europe and bring important new interventions to patients in need of them.

Read more

About EFPIA updates
Unsubscribe to be removed from this mailing list | Update your subscription

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 34 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels (Belgium)
Tel: +32 (0)2 626 25 55
Follow EFPIA
Twitter LinkedIn Youtube Google + Pinterest E-mail